Glioblastoma management in low and middle-income countries; existing challenges and policy recommendations
- PMID: 38021027
- PMCID: PMC10668069
- DOI: 10.1016/j.bas.2023.101775
Glioblastoma management in low and middle-income countries; existing challenges and policy recommendations
Abstract
Glioblastomas (GBM) are the most prevalent malignant CNS tumors globally, affecting about 3.19 per 100,000 people. The standard of care of GBM management includes surgical resection followed by radiotherapy and/or chemotherapy owing to the high recurrent rates. Despite the advances in neurosurgical practice and brain cancer research, low- and middle-income countries (LMICs) did not benefit greatly from these advances compared to high-income countries (HICs). First, the case ascertainment is low in LMICs, which contributes to a lower than actual disease burden and delayed presentation of the tumors with a worse prognosis. Second, GBM treatment is expensive; unregulated radiation and chemotherapy costs can expose the patients to financial hardships and lead to treatment discontinuation. Third, the lack of trained neurosurgical workforce in poor resource settings in LMICs further complicates the situation. Fourth, radiation therapy and chemotherapies are expensive and unavailable in many poor-resource settings in LMICs. Fifth, LMICs suffer from a weak infrastructure especially with low numbers of prepared ORs, laboratories, and advanced imaging techniques. In the present article, we highlight the major challenges of GBM management and further propose solutions for governments and health policy makers to improve GBM care in LMICs.
Keywords: GBM; Global neurosurgery; LMIC; Policy; Tumor.
© 2023 The Authors.
Conflict of interest statement
None to declare.
References
-
- Anjum K, Shagufta BI, Abbas SQ, Patel S, Khan I, Shah SAA, et al. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review. Biomed. Pharmacother. 2017 Aug;92:681–689. - PubMed
-
- Anjum K., Shagufta B.I., Abbas S.Q., Patel S., Khan I., Shah S.A.A., et al. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: a review. Biomed. Pharmacother. 2017;92:681–689. - PubMed
-
- Bell J.S., Koffie R.M., Rattani A., Dewan M.C., Baticulon R.E., Qureshi M.M., et al. Global incidence of brain and spinal tumors by geographic region and income level based on cancer registry data. J. Clin. Neurosci. 2019;66:121–127. - PubMed
-
- Cagney D.N., Alexander B.M. The cost and value of glioblastoma therapy. Expert Rev. Anticancer Ther. 2017;17(8):657–659. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
